soul trial oral semaglutide cardiovascular outcomes 2024 results nejm 2025 The (Semaglutide Trial) was a randomized ADA 2025: Oral Semaglutide soul trial oral semaglutide cardiovascular

doi: 10.1172/JCI104891 62 MalekASagerRZakherASchneiderH

Semaglutide is a unique medication developed by Novo Nordisk over a decade ago for treating type 2 diabetes

Learn more about the summit, and register here: #GLP1Summit #GLP1 #PrescriptionTrends #PrescribingTrends #PrescriptionData #Tirzepatide #Semaglutide #EHRData #ClinicalExpertLedAI #MedicalAI #HealthAI #HealthcareAI #AI #Innovation #RealWorldData #RWD Truvetas Post One week from today, our Director of Life Sciences Harshita Ravishankar, MD MPA, will be presenting at the inaugural GLP-1-Based Therapeutics Summit in Philadelphia on real-world GLP-1 prescribing trends gleaned from Truveta Data

And the outcomes remain to be determined